FDA approves first gene therapy for Duchenne muscular dystrophy, despite internal objections

被引:0
|
作者
Asher Mullard
机构
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:610 / 610
相关论文
共 50 条
  • [2] The FDA and Gene Therapy for Duchenne Muscular Dystrophy
    Rind, David M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (20): : 1705 - 1706
  • [3] FDA approves an HDAC inhibitor for Duchenne muscular dystrophy
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (05) : 329 - 329
  • [4] FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
    Aartsma-Rus, Annemieke
    Krieg, Arthur M.
    NUCLEIC ACID THERAPEUTICS, 2017, 27 (01) : 1 - +
  • [5] Gene therapy for Duchenne muscular dystrophy
    Suzuki, Naoki
    Miyagoe-Suzuki, Yuko
    Takeda, Shin'ichi
    FUTURE NEUROLOGY, 2007, 2 (01) : 87 - 96
  • [6] Gene therapy for Duchenne muscular dystrophy
    Ramos, Julian
    Chamberlain, Jeffrey S.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (11): : 1255 - 1266
  • [7] Duchenne Muscular Dystrophy Gene Therapy
    Saad, Fawzy A.
    Saad, Jasen F.
    Siciliano, Gabriele
    Merlini, Luciano
    Angelini, Corrado
    CURRENT GENE THERAPY, 2024, 24 (01) : 17 - 28
  • [8] Gene therapy for Duchenne muscular dystrophy
    Verhaart, Ingrid E. C.
    Aartsma-Rus, Annemieke
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (05) : 588 - 596
  • [9] Gene therapy of Duchenne muscular dystrophy
    Dickson, G
    CHEMISTRY & INDUSTRY, 1996, (08) : 294 - 297
  • [10] Gene Therapy for Duchenne Muscular Dystrophy
    Elangkovan, Nertiyan
    Dickson, George
    JOURNAL OF NEUROMUSCULAR DISEASES, 2021, 8 : S303 - S316